EX-10.4





 Exhibit 10.4 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO
THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933. 
 GRACE THERAPEUTICS INC. 

CONVERTIBLE PROMISSORY NOTE 
  

			
	
[US$                    ]
	  	[                    , 2018]

 For value received, Grace Therapeutics Inc., a Delaware corporation (the
“Company”), promises to pay to
                                        
(the “Holder”), the principal sum of
                                        
Dollars ($                ). Interest shall accrue from the date of this Note on the unpaid principal amount at a rate equal to six percent (6%) per annum,
compounded annually. This Note is one of a series of Convertible Promissory Notes containing substantially similar terms and conditions, each issued pursuant to a Convertible Note Purchase Agreement dated on or about the date of issuance of
such Note (the “Purchase Agreement”). Such Notes are referred to herein as the “Notes,” and the holders thereof are referred to herein as the “Holders.” This Note is subject to the following
terms and conditions. 
 1.    Maturity. Unless converted as provided in
Section 2, this Note will automatically mature and be due and payable on June 30, 2020 (the “Maturity Date”). Subject to Section 2 below, interest shall accrue on this Note but shall not be due and payable until the
Maturity Date. Notwithstanding the foregoing, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, shall become immediately due and payable upon the insolvency of the Company, the commission of any act of
bankruptcy by the Company, the execution by the Company of a general assignment for the benefit of creditors, the filing by or against the Company of a petition in bankruptcy or any petition for relief under the federal bankruptcy act or the
continuation of such petition without dismissal for a period of ninety (90) days or more, or the appointment of a receiver or trustee to take possession of the property or assets of the Company. 

2.    Conversion. 

(a)    Investment by the Holder. The entire principal amount of and accrued interest
on this Note shall be converted into shares of the Company’s equity securities (the “Equity Securities”) issued and sold at the close of the Company’s next equity financing in a single transaction or a series of related
transactions yielding gross proceeds to the Company of at least five million dollars ($5,000,000) in the aggregate (excluding the conversion of the Notes) (the “Next Equity Financing”). The number of shares of Equity Securities to
be issued upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) eighty five percent (85%) of the price per share of the Equity Securities being
offered in such Next Equity Financing, rounded to the nearest whole share, and the issuance of such shares upon such conversion shall be upon the terms and subject to the conditions applicable to the Next Equity Financing. 

(b)    Mechanics and Effect of Conversion. No fractional shares of the Company’s
capital stock will be issued upon conversion of this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the Company will pay to the Holder in cash the amount of the unconverted principal and interest balance of
this Note that would otherwise be converted into such fractional share. Upon conversion of this Note pursuant to this Section 2, the Holder shall surrender this Note, duly endorsed, at the principal offices of the Company or













 
any transfer agent of the Company. At its expense, the Company will, as soon as practicable thereafter, issue and deliver to such Holder, at such principal office, a certificate or certificates
for the number of shares to which such Holder is entitled upon such conversion, together with any other securities and property, if any, to which the Holder is entitled upon such conversion under the terms of this Note, including a check payable to
the Holder for any cash amounts payable as described herein. Upon conversion of this Note, the Company will be forever released from all of its obligations and liabilities under this Note with regard to that portion of the principal amount and
accrued interest being converted including without limitation the obligation to pay such portion of the principal amount and accrued interest. 

3.    Payment; Prepayment. All payments shall be made in lawful money of the United
States of America at such place as the Holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable and the remainder applied to principal. Prepayment of this
Note may be made at any time without penalty, provided that all of the Notes shall be prepaid on a pro rata basis. 

4.    Transfer; Successors and Assigns. The terms and conditions of this Note shall
inure to the benefit of and be binding upon the respective successors and assigns of the parties. Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer this Note without the prior written consent of the Company.
Subject to the preceding sentence, this Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the
Company. Thereupon, a new note for the same principal amount and interest will be issued to, and registered in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note. 

5.    Governing Law, Jurisdiction and Waiver of Jury Trial. This Note and all acts
and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. The
Company and the Holder (i) agree that any legal suit, action or proceeding arising out of or relating to this Note shall be instituted exclusively in federal or state courts located in the State of Delaware, (ii) waive any proceeding, and
(iii) irrevocably consent to the jurisdiction of the federal or state courts located in the State of Delaware in any such suit, action or proceeding. The Company and the Holder further agree to accept and acknowledge service of any and all
process which may be served in any such suit action or proceeding brought in the federal or state courts located in the State of Delaware and agree that service of process upon it mailed by certified mail to its address shall be deemed in every
respect effective service of process upon it in any suit, action or proceeding. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS NOTE OR THE TRANSACTIONS
CONTEMPLATED HEREBY. 
 6.    Notices. Any notice required or permitted by this
Agreement shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile, or forty eight (48) hours after being deposited in the U.S. mail as certified
or registered mail with postage prepaid, if such notice is addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice. 

7.    Amendments and Waivers. Any term of this Note may be amended only with the
written consent of the Company and Holders holding at least sixty six percent (66%) of the then-outstanding principal and interest of the Notes. Any amendment or waiver effected in accordance with this Section 7 shall be binding upon the
Company, each Holder and each transferee of any Note. 
 8.     Stockholders, Officers and
Directors Not Liable. In no event shall any stockholder, officer or director of the Company be liable for any amounts due or payable pursuant to this Note. 

  
 -2- 













 9.    Counterparts. This Note may
be executed in any number of counterparts, each of which will be deemed to be an original and all of which together will constitute a single agreement. 

10.    Loss of Note. Upon receipt by the Company of evidence satisfactory to it of
the loss, theft, destruction or mutilation of this Note or any Note exchanged for it, and indemnity satisfactory to the Company (in case of loss, theft or destruction) or surrender and cancellation of such Note (in the case of mutilation), the
Company will make and deliver in lieu of such Note a new Note of like tenor. 
 [Signature Page Follows] 

  
 -3- 













 The parties have executed this Convertible Promissory Note as of the date
first written above. 
  

			
	 COMPANY:

	
	 GRACE THERAPEUTICS INC.

		
	 By:
	 	  

	 Name:

	 Title:

	
	 Address:



  

			
	 AGREED TO AND ACCEPTED:

	
	 NAME OF HOLDER:

	
	 If an Entity:

		
	 Name:
	 	
		
	 By:
	 	  

	
	 Name:

	
	 Title:

		
	 Address:
	 	  

	
	  

	
	 If an Individual:

	  

	 Name:
	 	
		
	 Address: